Royal Bank of Canada Reiterates Outperform Rating for uniQure (NASDAQ:QURE)

Royal Bank of Canada restated their outperform rating on shares of uniQure (NASDAQ:QURE) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $24.00 price objective on the biotechnology company’s stock.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Wednesday, December 11th. The Goldman Sachs Group lifted their target price on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. Stifel Nicolaus upped their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Finally, Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.38.

uniQure Stock Performance

NASDAQ:QURE opened at $14.91 on Tuesday. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The firm has a 50 day simple moving average of $12.22 and a 200-day simple moving average of $8.48. The firm has a market cap of $726.71 million, a PE ratio of -3.01 and a beta of 0.41. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, equities analysts expect that uniQure will post -3.74 EPS for the current year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.74% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC increased its position in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in uniQure during the fourth quarter valued at approximately $88,000. Geode Capital Management LLC lifted its holdings in uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after buying an additional 6,362 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in uniQure by 14.6% during the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after buying an additional 8,642 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.